No Data
Express News | Beijing Tongrentang Group has completed the change of leadership and registered the business change, increasing the capital to 0.724 billion.
Zhongtai Securities: Traditional Chinese medicine companies are under pressure in the third quarter of 24Q3, with a slight rebound in end demand.
In Q3 2024, traditional Chinese medicine companies are facing temporary performance pressure, but the gross margin is expected to improve upwards starting in 2025.
beijing tongrentang (600085): The cost of traditional chinese medicine materials affects short-term profits, while revenue maintains a growth trend.
In the first three quarters of 2024, the company recorded revenue of 13.82 billion yuan, a year-on-year increase of 0.72%; net income attributable to shareholders was 1.35 billion yuan, a year-on-year decrease of 2.92%; the net income attributable to shareholders after deductions was 1.32 billion yuan, year-on-year.
Beijing Tongrentang (600085.SH): Currently not undertaking traditional Chinese medicine robot projects
Gelonghui November 8th, Beijing Tongrentang (600085.SH) stated on the interactive platform that the company's main business is the production and sales of Chinese patent medicine, and currently they have not launched Chinese medicine robot projects.
Beijing Tongrentang (600085): Nourishing Yin and Clearing Lung Pill launched in Canada, advancing the commercial sector's expansion.
Company Update: On November 1, 2024, the company announced that Beijing Tongrentang Pharmaceutical Factory's product Yinyang Qingfei Pill has been registered and launched in Canada. The approval of Beijing Tongrentang Pharmaceutical Factory's Yinyang Qingfei Pill by the Canadian Ministry of Health marks the issuance of the 'Product License (Class III).'
Deng Xiaofeng newly invested in a resource stock.
Private equity tycoons Feng Liu and Deng Xiaofeng's latest shareholdings are here! In the third quarter, High Yi Linshan No. 1 Horizon Fund managed by Feng Liu entered the list of the top ten circulating shareholders of 10 A-share companies, with a total market cap of approximately 19.538 billion yuan. Specifically, Feng Liu increased shareholdings in Beijing Tongrentang, Yantai Dongcheng Biochemicals, and Jonjee Hi-Tech Industrial and Commercial Holdings; reduced shareholdings in Angel Yeast Co., Ltd. and Nanjing King-Friend Biochemical Pharmaceutical; maintained its positions in Hangzhou Hikvision Digital Technology, LB Group Co., Ltd., shengyi technology, xinxiang richful lube additive, and Shanghai Titan Scientific Co.,Ltd. Deng Xiaofeng's High Yi Xiaofeng No. 2 Fund entered the list of the top ten circulating shareholders of 13 A-share companies in the third quarter, with a total market cap of approximately 7.917 billion yuan. High Yi Xiaofeng Hongyuan Fund
No Data
No Data